2018 San Antonio Breast Cancer Symposium (SABCS)

Evaluation of Multiple Transcriptomic Gene Risk Signatures in Male Breast Cancer (TBCRC 029)
Bayani J, Poncet C, Yao CQ, Crozier C, Neven A, Piper T, Cunningham C, Sobol M, Aebi S, Benstead K, Bogler O, Dal Lago L, Fraser J, Hibers F, Hedenfalk I, Korde L, Linderholm B, Martens J, Middleton L, Murray M, Kelly C, Nilsson C, Nowacyzk M, Peeters S, Peric A, Porter P, Schroder C, Rubio IT, Ruddy KJ, van Asperen C, Van Den Weyngaert D, van Deurzen C, van Leeuwen-Stok E, Vermeij J, Winer E, Boutros PC, Giordano SH, Cardoso F, Bartlett JMS
Poster: P6-19-01
Poster Session 6 on Saturday, December 8th from 7-9am CT in Hall 1

Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive (HR+) metastatic breast cancer (MBC) with prior chemotherapy for advanced disease (TBCRC 035) A phase II study with pharmacodynamics markers
Rugo HS, Mayer EL, Storniolo AM, Isaacs C, Mayer I, Stearns V, Nanda R, Nangia J, Wabl C, Deluca A, Kochupurakkal B, Wolff AC, Shapiro GI
Spotlight: PD2-12
Spotlight Session 2 on Wednesday, December 5th from 5-7pm CT in Stars at Night Ballroom 3 & 4- 3rd Level

2018 Publications

Tumor and Serum DNA Methylation in Women Receiving Preoperative Chemotherapy with or without Vorinostat in TBCRC 008
Connolly RM, Fackler MJ, Zhang Z, Zhou XC, Goetz MP, Boughey JC, Walsh B, Carpenter JG, Storniolo AM, Watkins SP, Gabrielson EW, Stearns V, Sukumar S
Breast Cancer Res Treat, 2018 Jan; PMID: 28918548

Concurrent Veliparib with Chest Wall and Nodal Radiotherapy in Patients with Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study
Jagsi R, Griffith KA, Bellon JR, Woodward WA, Horton JK, Ho A, Feng FY, Speers C, Overmoyer B, Sabel M, Schott A, Pierce L
J Clin Oncol, 2018 May 1; PMID: 29558281

TBCRC 026: Phase II Trial Correlating Standardized Uptake Value on FDG PET/CT With Pathologic Complete Response to Pertuzumab and Trastuzumab in HER2-positive Breast Cancer
Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey L, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V
J Clin Oncol, recently accepted

Molecular Determinants of Post-Mastectomy Breast Cancer Recurrence (TBCRC 027)
Keene KS, King T, Hwang ES, Peng B, McGuire KP, Tapia C, Zhang H, Bae S, Nakhlis F, Klauber-Demore N, Meszoely I, Sabel MS, Willey SC, Eterovic KA, Hudis C, Wolff AC, De Los Santos J, Thompson A, Mills GB, Meric Bernstam F
NPJ Breast Cancer, 2018 Oct 12; PMID: 30345349

2018 Additional Presentations

2018 American Society for Radiation Oncology (ASTRO) Annual Meeting

Gene Expression Changes Predict Acute and Late Toxicity to Combined PARP1 Inhibition and Radiation (RT) in High Risk Breast Cancer Patients- Results of the Biomarker Analysis of TBCRC 024
Speers C, Chandler B, Olsen E, Moubadder L, Thomas DG, Liu M, Griffith KA, Bellon JR,  Woodward WA, Horton JK, Ho A, Overmoyer B, Sabel M, Schott AF, Feng FY,  Pierce L,  Jagsi R
Abstract: #133; Oral Presentation: October 23rd from 7:55-8:05am CT
Int J of Rad Onc, 2018 Nov 1; Vol 102 (3), S67

2018 World Molecular Imaging Congress

Radiomic Features as Prognostic Biomarkers in Single-scan 18F-FDG PET Oncologic Imaging (TBCRC 026)
Leal JP, Connolly RM, Stearns V, Goetz MP, Storniolo AM, Carpenter J, Watkins S, Wahl RL, Solnes L
Poster: LBAP 051; Poster Session 02: September 13th from 3-4pm PT

2018 American Society of Clinical Oncology (ASCO) Annual Meeting

HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC 006/023 and PAMELA trials
Prat A, De Angelis C, Pascual T, Gutierrez C, Llombart-Cussac A, Wang T, Cortes J, Rexer BN, Veeraraghavan J, Forero-Torres A, Wolff AC, Morales S, Krop IE, Pavlick AC, Bermejo B, Hilsenbeck SG, Oliveira M, Schiff R, Osborne CK, Rimawi MF
Abstract: #509; Poster Board: #1; Poster Discussion Session: June 2nd from 8-11:30am CT

Clinical Evaluation of Germline Polymorphisms (SNPs) Associated with Disease Response to Capecitabine in Metastatic Breast Cancer (MBC) (TBCRC 015)
Choudhury N, Evans P, Ingle JN, Mayer IA, Morrow PKH, Storniolo AM, Forero-Torres A, Van Poznak CH, Merkel DE, Dees EC, Fleming GF, Hahn OM, Hoffman PC, Olopade OI, Cox N, Nanda R, O'Donnell PH
Abstract: #1071; Poster Board: #152; Poster Session: June 2nd from 8-11:30am CT

TBCRC 026: Phase II clinical trial assessing the correlation of standardized uptake value (SUV) on positron emission tomography (PET) with pathological complete response (pCR) to pertuzumab and trastuzumab in patients with primary operable HER2-positive breast cancer
Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey L, Liu M, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Wahl RL, Stearns V
Abstract: #511; Poster Board: #3; Poster Discussion Session: June 2nd from 8-11:30am CT

A randomized phase II study of pembrolizumab, an anti-PD (programmed cell death) 1 antibody, in combination with carboplatin compared to carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies (TBCRC 044)
Vidula N, Goga A, Hwang J, Liu MC, Park BH, Nanda R, Pohlmann PR, Storniolo AM, Brufsky A, Abramson VG, Rugo HS
Abstract: #TPS1113; Poster Board: #187b; Poster Session: June 2nd from 8-11:30am CT